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Abstract:  
Technology transfer is the process of transforming research and ideas into viable commercial opportunities. 
Notable examples of tech transfer include Google, artificial intelligence, life-saving vaccines, and renewable 
energy technology. Universities and colleges play an important role in the technology transfer process, 
ranging from brokering commercial partnerships, negotiating license agreements, and protecting 
intellectual property. Valuable patents are often at stake, and as a result, universities should anticipate 
litigation risks.  State universities, in particular, face new and unusual challenges as a result of their status as 
state entities. Under the 11th Amendment, state universities, as an arm of the state, can claim sovereign 
immunity, a doctrine which provides that the government cannot be sued without its consent. However, 
trends in litigation suggest that sovereign immunity protection for state universities is eroding.    
 
This article discusses the trends in litigation that implicate sovereign immunity claims by state universities 
embroiled in technology transfer disputes. The legal issues raised and discussed throughout the article are 
essential for technology transfer offices and university counsel to consider when reviewing their practices, 
policies, and litigation strategy.  The article also provides practical recommendations on how to shift risk 
away from the university.    
      
 
Introduction 
Under the 11th Amendment, can state 
universities assert sovereign immunity to avoid being 
sued by private parties in federal court for violation of 
patent laws? What implications does this constitutional 
tension have on technology transfer offices at state 
universities? The following narrative considers these 
two emerging questions through the interpretative 
lens of recent litigation and relevant statutory and 
constitutional provisions.  
As a practical starting point, the author 
provides a concise history of technology transfer in the 
United States. She then surveys the laws and legislation 
that govern the intersection between sovereign 
immunity and technology transfer, including the 11th 
Amendment and the Bayh-Dole Act. The article 
subsequently examines major themes in the case law 
that concern state universities’ use of sovereign 
immunity as a defense to litigation and then concludes 
by discussing the implications of sovereign immunity 
challenges on technology transfer offices at state 
universities.  
This article argues that state universities will 
face an increasing burden of litigation costs and a 
heightened risk of patent claims by third parties due to 
an erosion of state sovereign immunity. These long-
term repercussions could lead to negative downstream 
effects such as chilling technology transfer activity in 
the United States. Recommendations to insulate 
universities from litigation costs include special 
contract provisions, the use of arbitration, insurance 
policies, and selecting strategic partnerships for 
research discovery. The purpose of this article is to 
equip technology transfer offices with an overview of 
noteworthy holdings from relevant case law and 
practical measures to mitigate risk.        
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I. University Technology Transfer in 
the United States 
Historically, universities have enthusiastically 
entertained entrepreneurial partnerships between 
faculty members and industry players. One of the 
earliest ventures blossomed in California when 
chemistry professor Frederick Cottrell founded the 
Research Corporation in 1912.1 Cottrell’s intentions 
were to create a funding body to support scientific 
research and tackle environmental concerns such as 
pollution, an unanticipated product of the industrial 
revolution.2 Other collaborations between the academy 
and industry were born out of burgeoning growth in 
the agricultural economy and a need for new 
inventions (Etzkowitz, 2016). An increase in defense 
research spending quickly followed on the footsteps of 
World War II as completion of the Manhattan Project 
and other military research campaigns became 
missions of national importance (Mowery and 
Ziedonis, 2000). Over the decades, federal funding in 
academic research continued to flow into universities, 
while the scope of investment expanded to include 
engineering, physics, and biomedicine (Breznitz, 
2014).   
Unsurprisingly, American universities seized 
the opportunity to assist faculty with patent and 
licensing activities. Cottrell’s Research Corporation 
was also a recognized establishment for helping faculty 
with patent management.3 Globally, patent acquisition 
by universities commenced as early as 1921–1922 
when the University of Toronto acquired a patent on 
insulin, an anabolic hormone that was discovered by 
two researchers at the medical school (Bliss, 1982).   
With the increase in robust research activity 
and scientific discovery at major research institutions 
in the middle of the 20th century, federal funding 
agencies started to ask faculty members to assign their 
patents to the sponsoring agency.4 At the time, the 
prevailing attitude in government circles was well-
 
1 Research Corporation for Science Advancement. 
Retrieved from https://rescorp.org/rcsa/history 
2 Id. 
3 Id. 
4 American Association of University Professors. 
American University Patent Policies: A Brief History. 
Retrieved from 
https://www.aaup.org/sites/default/files/files/ShortHistory.
pdf 
understood: what the government (and public) pays 
for, it should own.5 This public policy catalyzed the 
federal government to acquire approximately 30,000 
patents by the 1960s.6 However, despite the good 
intentions of making federally funded research 
available for the public good, few inventions owned by 
the government were actually being commercialized 
(Feldman and Clayton, 2016).  
To remedy this problem, the federal 
government sought creative solutions. Understanding 
that universities were well equipped to advertise and 
find suitors to commercialize inventions, funding 
agencies agreed to use a new type of contract that 
would grant patent rights directly to universities. 
Better known as the Institutional Patent Agreement 
(IPA), this contract eliminated the cumbersome 
process of universities having to ask the Department of 
Health, Education, and Welfare (now, the HHS) to 
waive title to an invention (Berman, 2008). Waiver 
applications were complex, and IPAs were an efficient 
way for universities to cut through procedural red tape 
and initiate license agreements with industry 
partners.7 
II. Technology Transfer Legislation 
In addition to the use of IPAs between 
universities and federal agencies, three other notable 
events fostered a favorable environment for university 
technology transfer and intellectual property rights in 
the United States. The first event occurred in 1974 
when a group of research institutions founded the 
Society of University Patent Administrators (now 
known as the Association of University Technology 
Managers: AUTM) to promote the commercialization of 
academic research and to funnel inventions with high 
commercial potential to the marketplace so the general 
public could also reap the benefits of novel 
discoveries.8 Since its founding, the AUTM has 
facilitated the development of over 200 FDA-approved 
5 Wisconsin Alumni Research Foundation. WARF & the 
Bayh-Dole Act. Retrieved from 
https://www.warf.org/about-us/history/warf-bayh-dole-
act/warf-bayh-dole.cmsx  
6 Id.  
7 Id.  
8 AUTM. Mission & History. Retrieved from 
https://autm.net/about-autm/mission-history   
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drugs.9 The second event occurred in December 1980 
with the passage of the Bayh-Dole Patent and 
Trademark Amendments Act, which gave categorical 
permission to universities to retain patent rights to 
discoveries made with the support of federal funding 
(Breznitz, 2016). The third event occurred in 1982 
with the establishment of the U.S. Court of Appeals for 
the Federal Circuit, which serves as the court of final 
appeal for patent cases in the federal court system.10 
The Federal Circuit was established under Article III of 
the Constitution and has special jurisdiction over a 
variety of subject areas, including international trade, 
trademarks, and patents. Since the court’s inception, 
the Federal Circuit has been considered an advocate 
for intellectual property rights (Mowery and Ziedonis, 
2000).        
Researchers Woodell and Smith (2017) argue 
that the Bayh-Dole Act established the field of 
university technology transfer. The U.S. Department of 
Commerce, the federal agency that promotes 
technology transfer commercialization, delegated 
authority to the National Institute of Standards and 
Technology to promulgate rule-making for the Act.11 
Legislation similar to Bayh-Dole has been enacted 
worldwide, including in Singapore, Russia, the United 
Kingdom, and Mexico.12  
The following are major provisions of the 
Bayh-Dole Act, including new regulations, effective 
2018 (Lee, Riemenschneider, Altmann, Sherwood, 
2018).13 
 
• Universities may elect to retain title to 
discoveries made under federally funded 
research programs and must do so within two 
years following disclosure of the invention if 
election is made.  
• Universities must disclose subject inventions 
to the government within two months after 
the inventor discloses it to the university’s 
technology transfer office. 
• Universities are encouraged to collaborate 
with commercial entities to promote 
 
9 Id.  
10 United States Court of Appeals for the Federal Circuit. 
Court Jurisdiction. Retrieved from 
http://www.cafc.uscourts.gov/the-court/court-jurisdiction  
11 National Institute for Standards and Technology. 
(2020). Bayh-Dole Regulations for Federally Funded 
Inventions.  Retrieved from 
https://www.nist.gov/tpo/bayh-dole 
commercialization of research findings that 
benefit the public. 
• Universities are expected to file patents on 
inventions they elect to own. 
• If a federal employee is co-inventor of the 
subject invention, then the federal employee 
co-inventor may file the initial patent 
application, provided that the university 
retains the ability to elect rights.   This 
determination is made by the funding agency 
“at its discretion” and “in consultation with” 
the university.    
• Universities are expected to give licensing 
preference to small businesses and to those 
making products in the United States.  
• Universities automatically grant to the 
government a nonexclusive, irrevocable, paid-
up license to use the invention.  
• The government retains march-in rights under 
very specific circumstances. 
• Universities must obtain written agreement 
from employees of their responsibility to 
promptly disclose subject inventions in 
writing to technology transfer offices. 
• Universities must obtain written assignment 
agreements from employees, which assign all 
rights and titles to subject inventions to the 
university. 
• Following the discovery of non-compliance of 
the Bayh-Dole Act’s disclosure and election 
requirements, the government has an 
unlimited time to assert ownership to an 
invention.  
• Decisions to discontinue patent prosecution 
must be communicated to the government 
within 60 days before the statutory deadline.  
 
Related technology transfer legislation in the 
United States includes the Stevenson-Wydler 
Technology Innovation Act of 1980, which enabled 
government-owned and -operated laboratories to 
engage in cooperative research and development 
12 AUTM. Landmark Law Helped Universities Lead the 
Way. Retrieved from https://autm.net/about-tech-
transfer/advocacy/legislation/bayh-dole-act  
13 35 U.S.C. § 200–212; AUTM. The Bayh-Dole Act: It’s 
Working. Retrieved from 
https://autm.net/AUTM/media/About-Tech-
Transfer/Documents/BayhDoleTalkingPointsFINAL1193.
pdf   
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agreements14; the Federal Technology Transfer Act of 
1986, which allowed government inventors to patent 
their technologies and receive a portion of the royalties 
from commercialization15; and the America Invents Act 
of 2011, which reformed the patent system to be based 
on the “first inventor to file” rather than the “first to 
invent.”16   
11th Amendment Sovereign Immunity  
The intersection between sovereign immunity 
and technology transfer at state universities is a legal 
tension that is frequently under debate at the U.S. 
Court of Appeals for the Federal Circuit.17 Sovereign 
immunity is granted to state-owned universities 
because they are considered to be an arm of the state.18   
The laws that govern sovereign immunity are 
found in the 11th Amendment of the U.S. Constitution 
and also in common law that dates back to 1793.19 
Originating from English law, sovereign immunity is 
grounded in the theory of absolute divine rights 
whereby the king’s sovereign power is deemed to be 
God-given and unlimited (Choi, 2018). The power of 
the sovereign in medieval England effectively meant 
the king could do no harm (Borchard, 1924).      
The application of this legal doctrine in 
American jurisprudence was discussed in Chisolm v. 
Georgia, the result of which inspired Congress to enact 
the 11th Amendment of the Constitution so that states 
had the power to invoke immunity from suit by private 
parties in federal court (Choi, 2018): 
 
The Judicial power of the United States shall 
not be construed to extend to any suit in law 
or equity, commenced or prosecuted against 
one of the United States by Citizens of another 
State, or by Citizens or Subjects of any Foreign 
State.20  
 
 
14 Federal Laboratory Consortium. What is Technology 
Transfer? Retrieved from https://federallabs.org/learning-
center/what-is-t2   
15 15 U.S.C. §3710 
16 United States Patent and Trademark Office. Leahy-
Smith America Invents Act Implementation.  Retrieved 
from https://www.uspto.gov/patent/laws-and-
regulations/leahy-smith-america-invents-act-
implementation  
In simple terms, the 11th Amendment protects 
states from being forced to defend themselves against 
a private party. However, immunity is not absolute, 
and the Supreme Court has recognized two scenarios 
where a private party can sue a state: (1) when a state 
waives its sovereign immunity by consenting to the 
suit; and (2) when Congress exercises its 14th 
Amendment right to authorize a suit against a state.21 
While the first scenario is more straightforward in its 
application, the second scenario has caused a rift in 
Supreme Court judicial opinions such that recent 
holdings that curtail Congress’ power to abrogate state 
sovereign immunity have been deemed “judicial 
activism.”22  
III. Litigation Trends: University 
Technology Transfer and Sovereign 
Immunity Claims 
Technology transfer has become a breeding 
ground for litigious activity as a growing number of 
lawsuits between academics, universities, and industry 
reveal the web of tensions among these parties. Court 
cases involving university technology transfer were 
found through an online keyword search of WestLaw 
in February 2020: 220 cases were discovered using the 
keywords “university technology transfer” and 
“patent”; 130 cases were discovered using the 
keywords “university,” “patent,” and “sovereign 
immunity”; and 31 cases were discovered using the 
keywords “university technology transfer,” “patent,” 
and “sovereign immunity.” The narrow body of case 
law discussing sovereign immunity claims at state 
universities points to major themes that concern 
procedural issues, litigation conduct, original 
jurisdiction, administrative proceedings, and 
commercial activity by foreign states. 
17 Infra Part III 
18 Bd. of Regents of the Univ. of Tex. Sys v. Boston 
Scientific Corp, 936 F. 3d 1365 (2019). 
19 Chisolm v. Georgia, 2 U.S. 219 (1793).  
20 U.S. Const. amend. XI  
21 College Sav. Bank v. Florida Prepaid Postsecondary 
Educ. Expense Bd., 527 U.S. 666 (1999). 
22 Alden v. Maine, 527 U.S. 706 (1999); Seminole Tribe of 
Fla. v. Florida, 517 U.S. 44 (1996).  
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States Are Not Immune to Proper Transfers of 
Venue  
In Bd. of Regents of the Univ. of Tex. Sys v. 
Boston Scientific Corp, the Board of Regents of the 
University of Texas System (UT) and TissueGen, Inc. 
sued Boston Scientific Corporation for patent 
infringement in the Western District of Texas.23 The 
patents-in-suit concerned “implantable drug-releasing 
biodegradable fibers that replace the standard fibers 
used in medical devices, such as implantable stents.”24 
The fibers were discovered at the University of Texas 
System, and the university licensed the patents-in-suit 
to TissueGen, Inc., which was founded by the UT 
professor who co-discovered the technology.25  
In litigating the patent infringement claim, a 
procedural issue emerged. The district court 
determined that venue was improper in the Western 
District of Texas and transferred to the District of 
Delaware.26 The University of Texas sought venue in 
Texas by claiming sovereign immunity: 
 
Venue is proper in the Western District of 
Texas because UT is an arm of the State of 
Texas, has the same sovereign immunity as the 
State of Texas. It would offend the dignity of 
the State to require it to pursue persons who 
have harmed the State outside the territory of 
Texas, and the State of Texas cannot be 
compelled to respond to any counterclaims, 
whether compulsory or not, outside its 
territory due to the 11th Amendment.27 
 
The district court rejected UT’s sovereign 
immunity argument based on the longstanding rule 
that venue is proper where the defendant resides or 
 
23 Bd. of Regents of the Univ. of Tex. Sys v. Boston 
Scientific Corp, 936 F.3d 1365 (2019). 
24 Id.  
25 Id.  
26 Id.  
27 Id.  
28 Under the collateral order doctrine, the Federal Circuit 
agreed to hear the case on appeal despite the transfer order 
being interlocutory in nature. The Federal Circuit’s reason 
for hearing the appeal was because the transfer order was 
challenged on the basis of state sovereignty. See Puerto 
Rico Aqueduct and Sewer Authority v. Metcalf & Eddy, 
Inc., 506 U.S. 139 (1993). (“The Supreme Court held that 
States and State entities may invoke the collateral order 
has a regular and established place of business. Since 
defendant Boston Scientific Corporation was 
incorporated in Delaware, the court’s decision was 
logical. The district court explained that “sovereign 
immunity is a shield; it is not meant to be used as a 
sword … there is no claim or counterclaim against [UT] 
that places it in the position of the defendant” 
(emphasis added).28 On appeal, the Federal Circuit also 
rejected UT’s attempt to keep the case in Texas on the 
basis of sovereign immunity, holding that “the state 
sovereignty principles asserted by UT do not grant it 
the right to bring a patent infringement suit in an 
improper venue.”29 The Federal Circuit further noted 
that state sovereign immunity does not apply where 
the state acts solely as a plaintiff (emphasis added).30   
The outcome of the UT case has two 
implications: (1) state sovereignty principles do not 
give state universities the right to sue in an improper 
venue; and (2) a state cannot dictate where it litigates 
its property rights if the state is the sole plaintiff. Bd. of 
Regents of the Univ. of Tex. Sys v. Boston Scientific Corp 
also serves as a reminder that when a state or state 
entity voluntarily appears in federal court, it 
“voluntarily invokes the federal court’s jurisdiction” 
and must abide by federal rules and procedures.31     
Waiver of Sovereign Immunity Depends on 
Litigation Conduct  
In Xechem Intern., Inc. v. University of Tex. M.D. 
Anderson Cancer Center, the Federal Circuit considered 
the issue of whether the Board of Regents of the 
University of Texas System and the University of Texas 
M.D. Anderson Cancer Center could assert its 11th 
Amendment immunity to avoid a lawsuit in federal 
court.32 The lawsuit concerned a patent correction 
doctrine to immediately appeal an order denying a claim 
of sovereign immunity.”)  
29 Bd. of Regents of the Univ. of Tex. Sys v. Boston 
Scientific Corp, 936 F.3d 1365 (2019).  
30 But see A123 Systems, Inc. v. Hydro-Quebec, 626 F.3d. 
1213 (2010) (The Board of Regents of a State university 
could not be joined as a defendant because the State 
university had not waived 11th Amendment sovereign 
immunity in the lawsuit (emphasis added)).  
31 Lapides v. Bd. of Regents of the Univ. Sys. of Ga., 535 
U.S. 613 (2002).   
32 Xechem Intern., Inc. v. University of Tex. M.D. 
Anderson Cancer Center, 382 F. 3d 1324 (2004).  
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claim that stemmed from a collaboration between the 
university and Xechem International, a 
biopharmaceutical company that was developing the 
cancer drug paclitaxel.33 Xechem alleged that UT took 
several actions that equated to a waiver of sovereign 
immunity, such as entering into a collaborative 
research agreement.34    
To the contrary, the Federal Circuit held that 
none of UT’s actions were a waiver of sovereign 
immunity; instead, the court clarified that waiver of 
sovereign immunity should be “clear, explicit, and 
voluntary.”35 The court also echoed the opinion made 
in Bd. of Regents of the Univ. of Tex. Sys v. Boston 
Scientific Corp, which stressed the fact that a state’s 
voluntary entry into federal jurisdiction serves as a 
valid waiver.36  
In a similar set of facts relating to patent 
corrections, the Federal Circuit in Ali v. Carnegie Inst. of 
Washington discussed the impact of the Bayh-Dole Act 
with respect to the University of Massachusetts’ 
assertion of sovereign immunity.37 In particular, the 
court noted that just because the patents-in-suit 
resulted from federal funding through the Bayh-Dole 
Act does not mean that a university “makes a clear 
declaration” of its submission to federal court 
jurisdiction.38 In other words, a state’s waiver must not 
be implied or constructive. Furthermore, there is no 
“quid pro quo arrangement” whereby a contractual 
agreement between a state university and the federal 
government constitutes a waiver of sovereign 
immunity.39      
Waiver of Sovereign Immunity Through 
Voluntary Pursuit of Litigation  
By contrast, sovereign immunity is waived 
through aggressive pursuit of litigation in federal court. 
For example, in Vas-Cath, Inc. v. Curators of the Univ. of 
Mo., the Federal Circuit stated that the University of 
 
33 Id.  
34 Id. 
35 Id.  
36 Bd. of Regents of the Univ. of Tex. Sys v. Boston 
Scientific Corp, 936 F.3d 1365 (2019).  
37 Ali v. Carnegie Inst. of Washington, 684 F. Appx. 985 
(2017).   
38 Id.  
39 Id. at 25.  
Missouri waived its constitutional immunity by 
initiating and participating in a patent interference 
proceeding before the United States Patent and 
Trademark Office.40 Furthermore, the court held that 
the University of Missouri’s waiver at the patent 
proceeding level also applied at the appellate level. 
Similarly, in Regents of University of New Mexico v. 
Knight, the Federal Circuit declared that the University 
of New Mexico waived its sovereign immunity as to any 
compulsory counterclaims when it brought a patent 
ownership action against the inventors of cancer 
treatment compounds.41 Waiver can also be invoked by 
a defendant that voluntarily agrees to remove a case to 
federal court, which was seen in Lapides v. Board of 
Regents of University System of Georgia.42 By contrast, a 
state university’s filing of a patent infringement action 
does not waive sovereign immunity to a different suit 
in a different court involving the same parties.43  
These cases stress the fact that once a state 
university initiates a lawsuit in federal court, it 
consents to federal court jurisdiction and waives 11th 
Amendment immunity. The Supreme Court in Lapides 
explained this concept further:  
 
It would seem anomalous or inconsistent for a 
State both (1) to invoke federal jurisdiction, 
thereby contending that the “Judicial power of 
the United States” extends to the case at hand, 
and (2) to claim 11th Amendment immunity, 
thereby denying that the “Judicial power of the 
United States” extends to the case at hand. And 
a Constitution that permitted States to follow 
their litigation interests by freely asserting 
both claims in the same case could generate 
seriously unfair results.44   
 
More colloquially, the Supreme Court’s 
rationale to the University of Georgia was simple: “you 
can’t eat your cake and have it too” (Heywood, 1546).  
40 Vas-Cath, Inc. v. Curators of the Univ. of Mo., 473 F. 
3d 1376 (2007).   
41 Regents of University of New Mexico v. Knight, 321 F. 
3d 1111 (2003).  
42 Lapides v. Bd. of Regents of the Univ. Sys. of Ga., 535 
U.S. 613 (2002).   
43 Tegic Communications Corp. v. Board of Regents of 
University of Texas System, 458 F. 3d 1335 (2006).   
44 Lapides v. Board of Regents of University System of 
Georgia, 535 U.S. 613 (2002).  
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The Supreme Court Has Jurisdiction Over 
Suits Between State Universities  
The majority of cases discussing technology 
transfer at state universities and sovereign immunity 
involve a single state university and a private actor. 
However, in University of Utah v. Max-Planck-
Gesellschaft Zur Forderung Der Wissenschaften E.V., a 
state university brought a patent correction claim 
against another state university.45 The dispute 
concerned two professors who had presented about 
RNA interference issues at the same professional 
conferences and were familiar with one another’s 
work. When the University of Massachusetts’s 
professor filed for and was granted a patent, the 
University of Utah professor sued for a correction of 
patent ownership, claiming she was the rightful owner. 
Since the dispute arose between two state universities, 
the University of Massachusetts argued that the 
Supreme Court had jurisdiction over the dispute under 
the Constitution’s Original Jurisdiction clause.46  
The Federal Circuit held that the Supreme 
Court did not have exclusive jurisdiction over the 
patent claim between two state universities.47 The 
reasons provided by the court were complex but 
generally referred to the fact that (1) the University of 
Massachusetts was not an indispensable or real party 
of interest; and (2) the State has no core sovereign 
interest in inventorship.48 The Federal Circuit also 
reminded the universities that states do not enjoy 
sovereign immunity from suits brought by other 
states.49 The case was filed before the Supreme Court 
yet denied in 2014, meaning that the lower court 
decision stands. Interestingly, this case raises the 
question as to whether a state could ever have a 
sovereign interest in a patent invention.  
 
45 University of Utah v. Max-Planck-Gesellschaft Zur 
Forderung Der Wissenschaften E.V., 734 F. 3d 1315 
(2013).  
46 U.S. Const. art. III, § 2, cl. 2 (“In all Cases … in which 
a State shall be a Party, the [S]upreme Court shall have 
original Jurisdiction.”)   
47 University of Utah v. Max-Planck-Gesellschaft Zur 
Forderung Der Wissenschaften E.V., 734 F. 3d 1315 
(2013).  
48 Id.  
49 University of Utah v. Max-Planck-Gesellschaft Zur 
Forderung Der Wissenschaften E.V., 734 F. 3d 1315 
(2013); 
Texas v. New Mexico, 482 U.S. 124 (1987). 
Sovereign Immunity Does Not Bar Inter 
Partes Review  
Whether or not sovereign immunity can be 
invoked in an inter partes review (IPR) proceeding was 
discussed in Regents of the University of Minnesota v. 
LSI Corporation.50 Established in 2012, inter partes 
review is a trial proceeding conducted at the USPTO 
Patent Trial and Appeal Board to review the 
patentability of one or more claims in a patent.51 IPRs 
were created to address the public’s confidence and 
trust in the patent system by giving patent challengers 
an opportunity to purge bad patents through a re-
examination forum (Janis, 1997).52 In this case, the 
University of Minnesota brought a patent infringement 
action against a group of alleged infringers of the 
university’s semiconductor chip patents.53 In response, 
the alleged infringers subsequently filed petitions for 
inter partes review, but the University of Minnesota 
moved to dismiss the IPR proceedings based on 
sovereign immunity. The university argued that 
sovereign immunity applies to Article III proceedings 
and therefore should also apply to IPR proceedings.  
However, the Federal Circuit disagreed with 
the University of Minnesota, concluding that sovereign 
immunity does not apply to IPR proceedings because 
an IPR is “more like an agency enforcement action 
rather than a civil suit brought by a private party.”54 
Furthermore, the court noted that the Federal Rules of 
Civil Procedure do not apply in IPR proceedings and 
that petitioners do not have to be present for a final 
decision to be rendered by the Patent Trial and Appeal 
Board.55 The university filed suit before the Supreme 
50 Regents of the University of Minnesota v. LSI 
Corporation, 926 F. 3d 1327 (2019). 
51 United States Patent and Trademark Office. Inter Partes 
Review. Retrieved from https://www.uspto.gov/patents-
application-process/appealing-patent-decisions/trials/inter-
partes-review  
52 See S. Rep. No. 96–617, at 2–3, 14S. Rep. No. 96–617, 
at 2–3, 14 (1980); H.R. Rep. No. 96–1307, pt. 1, at 3 
(1980) (expressing concern as to the lack of confidence in 
the patent system). 
53 Regents of the University of Minnesota v. LSI 
Corporation, 926 F. 3d 1327 (2019). 
54 Id.  
55 Id.  
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Court, but this request was denied in 2020, leaving the 
Federal Circuit’s decision unchanged.56  
Several amici briefs, or briefs written by 
parties with a strong interest in the case, were filed by 
other state universities, which highlighted the 
potential harm that the Federal Circuit’s decision in 
Regents of the University of Minnesota would cause.57 
One of the major ramifications of the decision was both 
“practical and economic.”58 State universities would be 
forced to defend valuable patents in an increasing 
number of IPR proceedings, which cost roughly half a 
million dollars on average per proceeding.59 Another 
dire consequence of this decision is the chipping away 
of the structural division of power between states and 
the federal government that is guaranteed by the 
Constitution.  
Foreign Sovereign Immunities Act  
In Genetic Veterinary Sciences, Inc. v. LABOKLIN 
GmbH & Co KG, the Federal Circuit also addressed 
whether foreign universities can assert sovereign 
immunity in the U.S. federal judiciary.60 In the lower 
court proceedings, the University of Bern and 
LABOKLIN asserted a patent infringement claim 
against an American company (PPG) for using the 
university’s patent in tests that detect genetic diseases 
in dogs.61 In response, PPG asked the district court 
whether the patents-in-suit were ineligible for 
protection under § 101 for failing to claim patent-
eligible subject matter. When the district court 
determined that the patents were ineligible, the 
university and LABOKLIN appealed the decision, 
stating that the U.S. district court lacked personal and 
subject matter jurisdiction over the university because 
of sovereign immunity.  
Pursuant to the Foreign Sovereign Immunities 
Act (FSIA), the Federal Circuit explained that “a foreign 
 
56 Supreme Court of the United States Blog. Retrieved 
from https://www.scotusblog.com/case-files/cases/regents-
of-the-university-of-minnesota-v-lsi-corporation/ 
57 Id.  
58 Regents of the University of Minnesota v. LSI 
Corporation. (2019). Petition for Writ. Retrieved from 
https://www.supremecourt.gov/DocketPDF/19/19-
337/115569/20190912124127177_UMN%20Petition%20a
nd%20Appendix.pdf 
59 Id. 
60 Genetic Veterinary Sciences, Inc. v. LABOKLIN GmbH 
& Co KG, 933 F. 3d 1302 (2019).  
state is presumptively immune from the jurisdiction of 
United States courts,”62 unless a foreign state “engages 
in commercial activity … in the United States.”63 The 
Federal Circuit further explained that (1) obtaining U.S. 
patents and (2) enforcing patents through litigation or 
licensing activity are commercial activities for the 
purposes of determining jurisdiction under the FSIA.64 
This case is important for foreign universities who 
actively pursue commercial interests in the United 
States.    
IV. Implications for Technology 
Transfer Programs at State Universities 
Over the past several decades, federally 
funded technology transfer programs have fostered 
innovation and delivered a pipeline of novel, 
potentially life-changing discoveries to the public. For 
example, between 1969 and 2012, the USPTO issued 
over 75,000 patents to American universities (USPTO, 
2020). However, case law reveals that state 
universities may be dragged into more legal disputes 
despite their cry for sovereign immunity. This trend in 
litigation activity has three important implications for 
American innovation.  
First, state universities will suffer economic 
headwinds due to a rise in litigation costs from 
pursuing and defending patent claims. The holding in 
Regents of the University of Minnesota v. LSI Corporation 
is particularly worrisome given that the decision flings 
the door wide open for state universities to be hauled 
into new types of litigation proceedings, such as inter 
partes review. The problem with this type of tribunal is 
that a single patent or patent portfolio can be subjected 
to an unlimited number of administrative reviews by 
an unlimited number of petitioners.65 Furthermore, the 
costs of defending these claims would dramatically 
61 Genetic Veterinary Sciences, Inc. v. LABOKLIN GmbH 
& Co KG, 314 F. Supp 3d 727 (May, 2018).  
62 Saudi Arabia v. Nelson, 507 U.S. 349 (1993).  
63 28 U.S.C. § 1605(a)(2). 
64 Genetic Veterinary Sciences, Inc. v. LABOKLIN GmbH 
& Co KG, 933 F. 3d 1302 (2019); Intel Corp. v. 
Commonwealth Sci. & Indus. Research Org., 455 F.3d 
1364 (2006).  
65 Regents of the University of Minnesota v. LSI 
Corporation. (2019). Petition for Writ. Retrieved from 
https://www.supremecourt.gov/DocketPDF/19/19-
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constrain the budgets of state universities, which 
depend on revenues from intellectual property 
development for reinvestment in research and public 
education.66 Also, the cost to defend more legal 
disputes would prune the resources that state 
universities use to prosecute infringers of valuable 
university-owned patents.67    
The second implication is an overall negative 
impact on the social good due to a constricted 
downstream flow of new patent filings. With new 
litigation risks on the horizon, state universities may 
avoid filing patent applications for speculative 
innovations.68 This behavior not only deprives state 
universities of prospective revenue from patenting and 
licensing activities, it also stunts innovation as fewer 
discoveries trickle into the market. The long-term 
effect of overcaution by university technology transfer 
programs could mean fewer groundbreaking 
developments of the magnitude that have led to robust 
job growth and the creation of entire industries. If such 
effects come to fruition, the United States’ standing in 
the global innovation economy could eventually 
decline. The global shift in dynamics has already 
started to surface as China became the worldwide 
leader in patent filings in 2019 (Hosokawa, 2020). To 
further illustrate the probability of decreased 
technology transfer, an empirical study (Hvide and 
Jones, 2018) conducted in Norway revealed that a 
formal policy shift in rights from researcher to the 
university led to an approximate 50 percent drop in 
the rate of startups by university researchers between 
2000 - 2007, highlighting the sensitivity of the 
relationship between rights management and 
entrepreneurial activity.  
A third implication is that the decisions 
handed down by the Federal Circuit are a direct affront 
to the states’ right of sovereign immunity. By allowing 
 
337/115569/20190912124127177_UMN%20Petition%20a
nd%20Appendix.pdf 
66 Regents of the University of Minnesota v. LSI 
Corporation. (2019). Brief of the Association of Public 
and Land-Grant Universities as Amicus Curiae in Support 
of Petitioner.  Retreived from 
https://www.supremecourt.gov/DocketPDF/19/19-
337/118860/20191011163438730_2019-10-
11%20PDFA%20APLU%20Cert%20Stage%20Amicus%
20Brief%20-%20for%20Printer.pdf 
67 Id. 
68 Regents of the University of Minnesota v. LSI 
Corporation. (2019). Brief of Twelve State University 
states and state entities to be sued in administrative 
proceedings without its consent, federal courts are 
tarnishing the sovereign dignity of states and 
promoting an imbalance of powers within the legal 
system.  
This tension between federal and state power, 
a division that forms the basis of American federalism, 
is still hotly contested among Supreme Court justices. 
The debate roars in the dissents of cases such as Alden 
v. Maine, Kimel v. Florida Bd. of Regents, and Seminole 
Tribe.69 For example, the dissent in Alden points out 
that the right to sovereign immunity by states was 
curtailed when the Constitution was ratified in 1788.70 
Likewise, the dissent in Alden argues that Congress has 
the power to exercise its Article I power to abrogate 
state sovereign immunity.71 By contrast, the majority 
in Alden writes that the 10th Amendment, rather than 
the 11th, gives states the right to be immune from all 
suits “whether the court be state and federal, and 
whether the cause of action arises under state or 
federal law.”72 Under the majority’s reasoning, a state’s 
reliance on the 11th Amendment is unnecessary.73  
An unintended consequence of the developing 
body of case law discussing state sovereign immunity 
and technology transfer is that state sovereign 
immunity is eroding, despite the Supreme Court’s 
majority holdings that have advocated for state rights.     
V. Conclusion 
Protecting the culture of innovation within 
academia requires technology transfer offices to 
balance protection of intellectual property interests 
with prudent investment of federal funding into fruitful 
research and novel discoveries. Technology transfer 
programs at state universities have the additional 
burden of reserving adequate funds from state budgets 
Systems as Amici Curiae in Support of Petitioner.  
Retrieved from 
https://www.supremecourt.gov/DocketPDF/19/19-
337/119034/20191015154508370_19-
337%20Amicus%20Brief.pdf 
69 Alden v. Maine, 527 U.S. 706 (1999); Kimel v. Florida 
Bd. of Regents, 528 U.S. 62 (2000); Seminole Tribe of Fla. 
v. Florida, 517 U.S. 44 (1996).   
70 Alden v. Maine, 527 U.S. 706 (1999). 
71 Id. 
72 Id. 
73 Id. 
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to fend off patent trolls and other litigious creatures. 
Understanding the principles of when state 
universities can invoke sovereign immunity may save 
these institutions from unnecessary costs. 
Provided below is a summary of factors that 
determine when sovereign immunity is waived and 
when sovereign immunity is invoked by a state 
university. Although not exclusive given the ever-
expanding body of case law, this outline serves as a 
practical resource for technology transfer offices at 
state universities to consult.    
Sovereign Immunity Is NOT Waived: 
 
• Entering into a collaborative research 
agreement   
• Contracting with a private party in a license 
agreement for purposes of commercial gain 
• Entering into an arrangement controlled by 
federal law, such as patent licensing and 
royalties activity  
• The act of university employees applying for 
patents 
• Seeking the legal benefits of the USPTO 
• Filing patent applications with a federal 
agency  
• Calling for a correction to a patent 
• Invoking the authority of the USPTO to enforce 
patent rights  
• Obtaining federal funding through the Bayh-
Dole Act  
• Waiving sovereign immunity in one case while 
a different suit in a different court is 
concurrently being tried with the same parties 
Sovereign Immunity IS Waived:   
 
• Sovereign immunity should be clear, explicit, 
and voluntary. 
• A state’s voluntary entry into federal 
jurisdiction is a valid waiver.  
• Initiating a patent interference proceeding 
before the USPTO is a valid waiver.  
• Sovereign immunity as to compulsory 
counterclaims is also waived if a lawsuit is 
initiated by the state university. 
• If the state university (as defendant) agrees to 
remove a case to federal court, sovereign 
immunity is waived. 
• Sovereign immunity does not apply in inter 
partes review (IPR) proceedings.  
• Foreign universities waive sovereign 
immunity if they have obtained a U.S. patent, 
have been enforcing patents through litigation, 
or have been engaging in commercial activity 
in the United States. 
 
Below are recommendations on how 
technology transfer programs can shift risk away from 
the university:  
 
• Draft licensing agreements such that licensees 
assume a share of the litigation risk. 
• Consider strategic joint ventures with well-
funded entities.   
• Assess patent litigation risk through a 
comprehensive early-stage patent search. 
• Research competitors, marketing materials, 
industry practices, the international 
marketplace, technical publications, press 
releases, and shareholder announcements.  
• Consider the impact from a potential default 
judgment resulting from failure to participate 
in a voluntary inter partes review proceeding.  
• Invest in insurance for prospective patent 
disputes and demand insurance policy 
language that accurately and adequately 
provides relief.  
• Develop a risk management strategy.  
• Consider litigation financing to fund high-
stakes patent suits.  
• Pursue alternate forms of dispute resolution, 
such as mediation and arbitration, to mitigate 
the expense of litigation.  
• Consider pursuing litigation in international 
venues where laws are more favorable. 
• Eliminate co-invention scenarios where 
government employees are implicated in 
collaborative research. 
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